Are GLP-1 receptor agonists linked to higher psychological well being?

The latest enhance in GLP-1 (glucagon-like peptide-1) receptor agonist use not just for diabetes but additionally for weight reduction has dominated headlines over the previous few years. Nonetheless, how these medicine have an effect on one’s psychological well-being is much less nicely understood. There have been issues concerning the impression GLP-1 receptor agonists have on suicidal ideas. Some have additionally touted the potential advantages to psychological well being these medicine pose, together with lowered substance use and enhancements in temper. Higher clarifying how GLP-1s affect psychological well being, notably amongst these with pre-existing psychiatric sickness, is essential for informing remedy choices and understanding who one of the best candidates for such drugs could also be.

To start to deal with this hole within the literature, Taipale and colleagues (2026) used the nationwide Swedish well being registers to check using GLP-1 receptor agonists with non-use and with use of different second-line antidiabetic drugs amongst people with a pre-existing analysis of melancholy or nervousness. They had been particularly taken with understanding whether or not using this treatment is related to worsening psychological well being, in addition to worsening of substance use dysfunction and self-harm. The authors used a within-individual design, evaluating these interventions inside the identical individual (i.e., how an individual taking a GLP-1 compares with when that very same individual shouldn’t be taking a GLP-1).

GLP-1 receptor agonists are now widely prescribed for diabetes and obesity worldwide, but their effect on mental illness is unclear. — GLP-1 receptor agonists at the moment are extensively prescribed for diabetes and weight problems worldwide, however their impact on our psychological well being is unclear.

Strategies

The authors used Swedish nationwide well being registers to collect information from 95,490 members with a premorbid analysis of melancholy or nervousness who had been prescribed non-insulin antidiabetic treatment between 2009 and 2022, which had been analysed on this research utilizing a within-individual design.

The authors in contrast every individual’s danger of worsening psychological well being (outlined as a mixture of psychiatric hospitalisations, sick depart from work exceeding 14 days for psychiatric causes, hospitalisation as a result of self-harm, or loss of life by suicide) in periods of GLP-1 use in opposition to their danger once they weren’t utilizing the treatment. Secondary analyses additionally in contrast several types of antidiabetic drugs with each other inside the identical people. The within-individual design the authors used eliminates the results of traits that don’t change over time (e.g., persona, different comorbidities).

Outcomes

Among the many 95,490 members included on this research, the bulk had been feminine (59.7%) and had a analysis of tension (81.5%), although greater than half had a analysis of melancholy (54.9%) and a couple of third (36.4%) had each situations. A couple of quarter (23.5%) of the overall cohort had been prescribed GLP-1 receptor agonists, of whom 59.8% had been prescribed semaglutide and 46.9% liraglutide (some folks used a couple of GLP-1 throughout follow-up).

Desk 1: Danger throughout GLP-1 receptor agonist use in contrast with intervals of non-use in the identical folks
Consequence	Semaglutide	Liraglutide	Dulaglutide	Exenatide	Any GLP-1 receptor agonist
Worsening psychological sickness (most important consequence)	0.58 (0.51 to 0.65)	0.82 (0.76 to 0.89)	1.01 (0.85 to 1.20)	1.01 (0.69 to 1.46)	0.76 (0.71 to 0.82)
Psychiatric or self-harm hospitalisation	0.72 (0.59 to 0.89)	0.89 (0.76 to 1.05)	1.09 (0.83 to 1.44)	1.28 (0.61 to 2.68)	Not reported
Sick depart over 14 days for psychiatric causes	0.55 (0.47 to 0.64)	0.88 (0.80 to 0.97)	0.92 (0.73 to 1.16)	1.14 (0.73 to 1.76)	Not reported
Worsening melancholy	0.56 (0.44 to 0.71)	0.74 (0.64 to 0.87)	0.71 (0.51 to 1.01)	1.40 (0.74 to 2.62)	0.70 (0.62 to 0.79)
Worsening nervousness	0.62 (0.52 to 0.73)	0.91 (0.81 to 1.02)	1.11 (0.86 to 1.44)	1.20 (0.73 to 1.99)	0.84 (0.76 to 0.92)
Worsening substance use dysfunction	0.53 (0.35 to 0.80)	1.05 (0.80 to 1.38)	1.01 (0.60 to 1.72)	Too few occasions	0.84 (0.68 to 1.04)
Hospital-treated self-harm	0.51 (0.20 to 1.28)	0.54 (0.28 to 1.07)	0.39 (0.14 to 1.09)	Too few occasions	0.56 (0.34 to 0.92)

Adjusted hazard ratio (95% confidence interval). Values beneath 1 imply decrease danger. Daring means statistically vital. Exenatide outcomes for substance use and self-harm weren’t reported as a result of there have been fewer than 10 occasions. Knowledge from Taipale et al. (2026), figures 1 to 4.

Use of each semaglutide and liraglutide was related to decreased worsening of psychological well being issues in contrast with intervals when the identical people didn’t use GLP-1s. When semaglutide was in contrast with different GLP-1 Receptor agonists, semaglutide was related to a considerably decreased danger of worsening psychological well being issues. Ladies and men didn’t considerably differ of their decreased danger of worsening psychological well being issues throughout all GLP-1 receptor agonists besides liraglutide, for which there was solely a decreased danger of worsening psychological well being issues in girls, however not in males.

Concerning particular components of worsening psychological well being issues, semaglutide was related to a lowered danger of worsening melancholy, worsening nervousness, and worsening substance use, however liraglutide was solely related to a lowered danger of worsening melancholy. Any use of GLP-1 receptor agonists was related to lowered danger of self-harm. Amongst inpatient occasions, semaglutide was related to a lowered danger of psychiatric or self-harm hospitalisation. Each semaglutide and liraglutide had been additionally related to a decrease danger of sick depart as a result of any psychiatric cause. Compared with different second-line antidiabetics, semaglutide was once more related to a decrease danger of worsening psychological well being issues, whereas dapagliflozin and sitagliptin had been linked to a larger danger of worsening psychological well being issues in contrast with empagliflozin.

Desk 2: Danger of worsening psychological sickness in contrast with empagliflozin
Medicine	Adjusted hazard ratio (95% confidence interval)	In contrast with empagliflozin
Semaglutide	0.73 (0.62 to 0.87)	Decrease danger
Liraglutide	1.14 (1.00 to 1.30)	No clear distinction
Dapagliflozin	1.24 (1.02 to 1.52)	Increased danger
Sitagliptin	1.49 (1.31 to 1.68)	Increased danger

Comparisons are inside the identical folks, utilizing intervals when just one second-line antidiabetic was taken (metformin was allowed all through). Daring means statistically vital. Knowledge from Taipale et al. (2026), determine 5.

Semaglutide confirmed the strongest affiliation with lowered danger of worsening melancholy, nervousness and substance use dysfunction; the impact was smaller and fewer constant for liraglutide.

Conclusions

The authors concluded that, amongst folks with established melancholy or nervousness who had been additionally being handled with an antidiabetic, semaglutide and (to a lesser extent) liraglutide had been related to considerably decrease danger of worsening psychological well being issues in contrast with intervals of time once they weren’t utilizing these drugs, whereas exenatide and dulaglutide weren’t.

They counsel that these findings point out differing GLP-1s might have totally different advantages, although they be aware that GLP-1 receptor agonists as a gaggle had been related to a decrease danger of self-harm (the research lacked the facility to check particular person medicine). The authors name for a future randomised managed trial of GLP-1 receptor agonist use in folks with diabetes and melancholy, nervousness, or each psychiatric situations to enhance understanding of the precise advantages GLP-1 receptor agonists might have in these populations.

The authors call for randomised controlled trials to confirm whether GLP-1 receptor agonists genuinely protect mental health, rather than simply reflecting other factors linked to their use. — The authors name for randomised managed trials to verify whether or not GLP-1 receptor agonists genuinely defend psychological well being, quite than merely reflecting different components linked to their use.

Strengths and limitations

The usage of a within-individual design is by far the best power of this research. By having every individual act as their very own comparator, the research removes the impact of secure variations between individuals who take GLP-1s and people who don’t (akin to persona or baseline sickness severity). It may possibly’t rule out components that change over time, akin to why somebody begins or stops the drug, and the authors acknowledge attainable residual confounding. Furthermore, the very massive pattern measurement offers the research the facility to detect modest associations.

One limitation of this research is the absence of medical severity measures. The authors had been unable to look at to what extent the lowered danger of worsening psychological well being issues seen throughout treatment use intervals is a mirrored image of adjustments in weight or symptom severity that is perhaps anticipated throughout treatment use. Moreover, there have been considerably smaller samples in analyses of dulaglutide and exenatide. Due to this fact, the null findings for these medicine could also be a difficulty of energy quite than an absence of impact.

One other limitation of this research is that there have been various indications for using GLP-1 receptor agonists among the many research cohort, and it’s unclear whether or not the indication (for instance, somebody taking the treatment for diabetes vs. for weight reduction) was related to variations in danger of worsening psychological well being issues. Equally, because the majority of members included on this research had been prescribed these drugs for diabetes, replicating this research with a pattern of members solely taking GLP-1 receptor agonists for weight reduction is essential to generalise the findings to an ever-increasing group of people now prescribed GLP-1 receptor agonists for this indication.

Sweden's linked national registers allowed the researchers to track prescriptions, hospitalisations, sick leave, and cause of death for the same individuals over more than a decade. — Sweden’s linked nationwide registers allowed the researchers to trace prescriptions, hospitalisations, sick depart, and explanation for loss of life for a similar people over greater than a decade.

Implications for observe

This research is a crucial first step in understanding how GLP-1 receptor agonists might have an effect on psychological well being amongst people with diabetes or weight problems and comorbid melancholy or nervousness. The findings counsel that maybe GLP-1 use might assist with psychological well being alongside bodily well being. Nonetheless, a randomised managed trial is required to higher perceive these preliminary findings.

For prescribers, these outcomes additionally counsel that every GLP-1 receptor agonist might have totally different results on psychological well being. The findings additionally counsel that semaglutide could also be a smart choice for folks with diabetes and a pre-existing analysis of melancholy or nervousness; the case for liraglutide is weaker, because it did no higher than empagliflozin within the head-to-head comparability. Nonetheless, on condition that these findings haven’t but been replicated in a randomised managed trial and due to particular person variations, you will need to assess and monitor adjustments in every particular person’s psychological well being signs all through remedy and regulate accordingly.

Until trial data are available, clinicians may want to track mental health symptoms closely when prescribing GLP-1 receptor agonists to patients with depression or anxiety. — Till trial information can be found, clinicians might need to observe psychological well being signs intently when prescribing GLP-1 receptor agonists to sufferers with melancholy or nervousness.

Assertion of pursuits

Alexandra Allam has no conflicts of curiosity to declare, however acknowledges AI (Claude, Anthropic) use to assist with the modifying of the weblog textual content.